CAG
AXSM icon

Csenge Advisory Group’s Axsome Therapeutics AXSM Stock Holding History

Csenge Advisory Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$506K Sell
2,067
-740
-26% -$160K 0.02% 460
2026
Q1 		$474K Sell
2,807
-1,189
-30% -$205K 0.02% 444
2025
Q4 		$730K Buy
+3,996
New +$558K 0.03% 361

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Csenge Advisory Group's AXSM Position: Q2 2026 in Review

Csenge Advisory Group reduced its Axsome Therapeutics (AXSM) stake by 26% in Q2 2026, selling an estimated $160K and leaving 2,067 shares worth $506K. The position accounts for 0.02% of the portfolio, ranked #460.

Csenge Advisory Group first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. The position peaked at $730K in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Csenge Advisory Group held 2,067 shares of Axsome Therapeutics worth $506K as of Q2 2026.
  • Csenge Advisory Group sold 740 Axsome Therapeutics shares in Q2 2026, an estimated $160K.
  • Axsome Therapeutics made up 0.02% of Csenge Advisory Group's portfolio in Q2 2026, its #460 holding.
  • Csenge Advisory Group first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Csenge Advisory Group's Axsome Therapeutics position peaked at $730K in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Csenge Advisory Group's 13F filing for Q2 2026, filed 10 Aug 2026.